HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.

AbstractBACKGROUND:
The tumor protein p53 (TP53) arginine-to-histidine mutation at codon 337 (R337H) predisposes children to adrenocortical tumors (ACTs) and, rarely, to other childhood tumors, but its impact on adult cancer remains undetermined. The objective of this study was to investigate the frequency and types of cancer in relatives of children with ACT who carry the TP53 R337H mutation.
METHODS:
TP53 R337H testing was offered to relatives of probands with ACT. The parental lineage segregating the R337H mutation was identified in all families. The frequency and distribution of cancer types were compared according to R337H status. The authors' data also were compared with those publicly available for children with TP53 mutations other than R337H.
RESULTS:
The mean and median follow-up times for the probands with ACT were 11.2 years and 9.7 years (range, 3-32 years), respectively. During this time, cancer was diagnosed in 12 of 81 first-degree relatives (14.8%) carrying the R337H mutation but in only 1 of 94 noncarriers (1.1%; P = .0022). At age 45 years, the cumulative risk of cancer was 21% (95% confidence interval, 5%-33%) in carriers and 2% (95% confidence interval, 0%-4%) in noncarriers (P = .008). The frequency of cancer was higher in the R337H segregating lineages than in the nonsegregating lineages (249 of 1410 vs 66 of 984 individuals; P < .001). Breast and gastric cancer were the most common types.
CONCLUSIONS:
TP53 R337H carriers have a lifelong predisposition to cancer with a bimodal age distribution: 1 peak, represented by ACT, occurs in the first decade of life, and another peak of diverse cancer types occurs in the fifth decade. The current findings have implications for genetic counseling and surveillance of R337H carriers. Cancer 2017;123:3150-58. © 2017 American Cancer Society.
AuthorsMaria J Mastellaro, Ana L Seidinger, Guolian Kang, Renata Abrahão, Eliana C M Miranda, Stanley B Pounds, Izilda A Cardinalli, Simone S Aguiar, Bonald C Figueiredo, Carlos Rodriguez-Galindo, Silvia R Brandalise, José A Yunes, Antônio de A Barros-Filho, Raul C Ribeiro
JournalCancer (Cancer) Vol. 123 Issue 16 Pg. 3150-3158 (Aug 15 2017) ISSN: 1097-0142 [Electronic] United States
PMID28387921 (Publication Type: Journal Article)
Copyright© 2017 American Cancer Society.
Chemical References
  • TP53 protein, human
  • Tumor Suppressor Protein p53
Topics
  • Adolescent
  • Adrenal Cortex Neoplasms (genetics)
  • Adult
  • Brazil
  • Breast Neoplasms (genetics)
  • Child
  • Child, Preschool
  • Family
  • Female
  • Genetic Predisposition to Disease
  • Heterozygote
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Neoplasms (genetics)
  • Stomach Neoplasms (genetics)
  • Tumor Suppressor Protein p53 (genetics)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: